Phase I of BKM120/Olaparib for Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Study identifier: NCT01623349
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
- Recurrent ovarian Cancer (high grade serous carcinoma). Prior therapy must have included platinum-based drug.
- Metastatic triple negative breast cancer, and at least 1 chemotherapy regimen for metastatic breast cancer or developed metastatic breast cancer within 1 year of completion of adjuvant chemotherapy,
Type of study:
Phase I study
Escalating doses of oral olaparib twice daily and oral BKM120 (an oral PI3 Kinase inhibitor) once daily
Massachusetts General Hospital
Contact: Meghan Comeau 617-726-0491 email@example.com
Memorial Sloan-Kettering Cancer Center
Contact: Sara Kravetz 646-888-4423 firstname.lastname@example.org
MD Anderson Cancer Center
Contact: Michael Garcia, RN 713-794-1421 email@example.com
Page updated 06/13/13
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.